

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Pharmaceutical Obtains Manufacturing and Marketing Approval for DroEthiFlex® COMBINATION TABLETS “ASKA”

TOKYO, August 17, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi) announced that its subsidiary, ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi; hereinafter “ASKA Pharmaceutical”), has obtained manufacturing and marketing approval in Japan for DroEthiFlex® COMBINATION TABLETS “ASKA”, a therapeutic agent for the relief of pain associated with endometriosis and the treatment of dysmenorrhea.

ASKA Pharmaceutical will proceed with preparations for the product launch following its listing in the National Health Insurance (NHI) drug price standard.

As a specialty healthcare company, ASKA Pharmaceutical will continue to expand its portfolio of obstetrics and gynecology-related products.

Product Overview

Item	Description
Product Name	DroEthiFlex® COMBINATION TABLETS “ASKA”
Generic Name	Drospirenone and Ethinylestradiol Tablets
Indications	• Improvement of pain associated with endometriosis • Dysmenorrhea • Adjustment of the timing of initiation of controlled ovarian stimulation in assisted reproductive technology (ART)

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp